Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...
Johnson & Johnson said Monday it expects to accelerate sales growth beyond Wall Street expectations in the field of ...
MarketBeat on MSN5d
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?Johnson & Johnson (NYSE: JNJ) stock is up 1.8% in the five days after the company announced its $14.6 billion acquisition of ...
Johnson & Johnson (JNJ) and Intra-Cellular Therapies, Inc. (ITCI) announced Monday that they have entered into a definitive agreement ...
Johnson & Johnson (NYSE: JNJ) and Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) announced today that they have entered into a definitive agreement under which Johnson & Johnson will acquire all ...
Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system ...
Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...
Johnson & Johnson has agreed to acquire all outstanding shares of Intra-Cellular Therapies Inc., a biopharmaceutical company ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback